Fenwick represented Scribe Therapeutics, a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, in its expanded collaboration with Sanofi (NASDAQ: SNY). Under the agreement, Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies, including sickle cell disease. The agreement follows the launch of the companies’ existing collaboration focused on ex vivo editing of natural killer (NK) cell therapies for the treatment of cancer.
Under the terms of the agreement, Scribe will receive $40 million in upfront payment and is eligible to potentially receive more than $1.2 billion based on the successful completion of certain development and sales milestones. Scribe will also be eligible to receive tiered royalties that range from high single digits to low double digits on net future sales on any products that may result from this agreement. Scribe has a right to opt-in to development cost sharing, as well as co-promotion and profit and loss sharing in the U.S. on one future program. More information about the collaboration can be obtained from the announcement.
The Fenwick transaction team was led by life sciences partner Stefano Quintini and included partner Jake Handy and associate Leanne Ta.